Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; Biomedical Advanced Research and Development Authority; US Department of Defense; and PCI Biotech. The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgård, Denmark.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone45-3326-8383
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$208.06 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/25/2019 (Estimated)
OptionableNot Optionable
BAVARIAN NORDIC/S (OTCMKTS:BVNRY) Frequently Asked Questions
What is BAVARIAN NORDIC/S's stock symbol?
BAVARIAN NORDIC/S trades on the OTCMKTS under the ticker symbol "BVNRY."
When is BAVARIAN NORDIC/S's next earnings date?
Has BAVARIAN NORDIC/S been receiving favorable news coverage?
News stories about BVNRY stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BAVARIAN NORDIC/S earned a news impact score of -1.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of BAVARIAN NORDIC/S's key competitors?
Some companies that are related to BAVARIAN NORDIC/S include Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), Momenta Pharmaceuticals (MNTA), Orchard Therapeutics (ORTX), Rubius Therapeutics (RUBY), Alector (ALEC), Iovance Biotherapeutics (IOVA) and Fate Therapeutics (FATE).
What other stocks do shareholders of BAVARIAN NORDIC/S own?
Who are BAVARIAN NORDIC/S's key executives?
BAVARIAN NORDIC/S's management team includes the folowing people:
- Dr. Paul Chaplin, CEO & Pres (Age 52)
- Mr. Henrik Juuel, CFO & Exec. VP (Age 54)
- Mr. Henrik Birk, COO & Exec. VP (Age 45)
- Dr. Christopher R. Heery, Chief Medical Officer
- Dr. Tommi Kainu M.D., Ph.D., Exec. VP, Chief Bus. Officer & Member of the Exec. Management (Age 46)
How do I buy shares of BAVARIAN NORDIC/S?
Shares of BVNRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BAVARIAN NORDIC/S's stock price today?
One share of BVNRY stock can currently be purchased for approximately $7.10.
How big of a company is BAVARIAN NORDIC/S?
BAVARIAN NORDIC/S has a market capitalization of $688.20 million and generates $208.06 million in revenue each year. The company earns $27.54 million in net income (profit) each year or $0.29 on an earnings per share basis.
What is BAVARIAN NORDIC/S's official website?
How can I contact BAVARIAN NORDIC/S?
BAVARIAN NORDIC/S's mailing address is Hejreskovvej 10A, Kvistgaard G7, 3490. The company can be reached via phone at 45-3326-8383 or via email at [email protected]
MarketBeat Community Rating for BAVARIAN NORDIC/S (OTCMKTS BVNRY)
MarketBeat's community ratings are surveys of what our community members think about BAVARIAN NORDIC/S and other stocks. Vote "Outperform" if you believe BVNRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BVNRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
